Jones G et al., Ann Rheum Dis 2009: Online 17 March 2009. doi:10.1136/ard.2008.105197: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.
RECOVERY Collaborative Group: Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. In: The Lancet. Band397, Nr.10285, 1. Mai 2021, S.1637–1645, doi:10.1016/S0140-6736(21)00676-0, PMID 33933206.
The REMAP-CAP Investigators, Lennie P.G. Derde: Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. In: MedRxiv. 25. Juni 2021, doi:10.1101/2021.06.18.21259133 (medrxiv.org [abgerufen am 10. August 2021]).
JV Perez-Moreiras, JJ Gomez-Reino, JR Maneiro, E Perez-Pampin, A Romo Lopez, FM Rodríguez Alvarez, JM Castillo Laguarta, A Del Estad Cabello, M Gessa Sorroche, E España Gregori, M Sales-Sanz, Group. Tocilizumab in Graves Orbitopathy Study: Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. In: American journal of ophthalmology. 195. Jahrgang, November 2018, S.181–190, doi:10.1016/j.ajo.2018.07.038, PMID 30081019.
L Sánchez-Bilbao, D Martínez-López, M Revenga, Á López-Vázquez, E Valls-Pascual, B Atienza-Mateo, B Valls-Espinosa, O Maiz-Alonso, A Blanco, I Torre-Salaberri, V Rodríguez-Méndez, Á García-Aparicio, R Veroz-González, V Jovaní, D Peiteado, M Sánchez-Orgaz, E Tomero, FJ Toyos-Sáenz de Miera, V Pinillos, E Aurrecoechea, Á Mora, A Conesa, M Fernández-Prada, JA Troyano, V Calvo-Río, R Demetrio-Pablo, Í González-Mazón, JL Hernández, S Castañeda, MÁ González-Gay, R Blanco: Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. In: Journal of clinical medicine. 9. Jahrgang, Nr.9, 31. August 2020, doi:10.3390/jcm9092816, PMID 32878150.
Dr. med. Markus Harwart: Die Entwicklung von Tocilizumab – Medizinischer Fortschritt auf Basis einer erfolgreichen Kooperation von Chugai und Roche.
medrxiv.org
The REMAP-CAP Investigators, Lennie P.G. Derde: Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. In: MedRxiv. 25. Juni 2021, doi:10.1101/2021.06.18.21259133 (medrxiv.org [abgerufen am 10. August 2021]).
nih.gov
ncbi.nlm.nih.gov
RECOVERY Collaborative Group: Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. In: The Lancet. Band397, Nr.10285, 1. Mai 2021, S.1637–1645, doi:10.1016/S0140-6736(21)00676-0, PMID 33933206.
JV Perez-Moreiras, JJ Gomez-Reino, JR Maneiro, E Perez-Pampin, A Romo Lopez, FM Rodríguez Alvarez, JM Castillo Laguarta, A Del Estad Cabello, M Gessa Sorroche, E España Gregori, M Sales-Sanz, Group. Tocilizumab in Graves Orbitopathy Study: Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. In: American journal of ophthalmology. 195. Jahrgang, November 2018, S.181–190, doi:10.1016/j.ajo.2018.07.038, PMID 30081019.
L Sánchez-Bilbao, D Martínez-López, M Revenga, Á López-Vázquez, E Valls-Pascual, B Atienza-Mateo, B Valls-Espinosa, O Maiz-Alonso, A Blanco, I Torre-Salaberri, V Rodríguez-Méndez, Á García-Aparicio, R Veroz-González, V Jovaní, D Peiteado, M Sánchez-Orgaz, E Tomero, FJ Toyos-Sáenz de Miera, V Pinillos, E Aurrecoechea, Á Mora, A Conesa, M Fernández-Prada, JA Troyano, V Calvo-Río, R Demetrio-Pablo, Í González-Mazón, JL Hernández, S Castañeda, MÁ González-Gay, R Blanco: Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. In: Journal of clinical medicine. 9. Jahrgang, Nr.9, 31. August 2020, doi:10.3390/jcm9092816, PMID 32878150.